Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 2/20 | 0.55 |
| ▸ | GAA | P10253 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | PLK4 | O00444 | 1/20 | 0.54 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.54 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.54 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.54 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.54 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.54 |
| ▸ | CDK1 | P06493 | 1/20 | 0.54 |
| ▸ | PIM1 | P11309 | 1/20 | 0.54 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.54 |
| ▸ | CDK2 | P24941 | 1/20 | 0.54 |
| ▸ | FLT4 | P35916 | 1/20 | 0.54 |
| ▸ | KDR | P35968 | 1/20 | 0.54 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.54 |
| ▸ | CDK8 | P49336 | 1/20 | 0.54 |
| ▸ | CLK2 | P49760 | 1/20 | 0.54 |
| ▸ | GSK3A | P49840 | 1/20 | 0.54 |
| ▸ | GSK3B | P49841 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4379039 | 0.94 | ACHE (0.53) | HTTGAAMAPTPLK4CHEK1 | |
| SCHEMBL4560545 | 0.92 | CHEK1 (0.51) | HTTGAAMAPTPLK4CHEK1 | |
| SCHEMBL4560546 | 0.81 | HTT (0.43) | HTTGAAMAPTBCHEACHE | |
| SCHEMBL4379043 | 0.79 | ACHE (0.50) | HTTGAAMAPTBCHEACHE | |
| SCHEMBL9208663 | 0.78 | HTT (0.74) | HTTGAAMAPTBCHEACHE | |
| SCHEMBL9749208 | 0.78 | HTT (0.64) | HTTGAAMAPTBCHEACHE | |
| SCHEMBL8473136 | 0.77 | HTT (0.69) | HTTGAAMAPTBCHEACHE | |
| SCHEMBL8472225 | 0.76 | HTT (0.71) | HTTGAAMAPTBCHEACHE | |
| SCHEMBL10061487 | 0.76 | HTT (0.67) | HTTGAAMAPTBCHEACHE | |
| SCHEMBL8476129 | 0.75 | HTT (0.73) | HTTGAAMAPTBCHEACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9856234-B2 | Heterocyclic compounds and their use as glycogen synthase kinase 3 inhibitors | AbbVie Deutschland GmbH & Co. KG (DE) | 2018-01-02 | — | — | US | claimed |
| US-20140148458-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS GLYCOGEN SYNTHASE KINASE 3 INHIBITORS | AbbVie Deutschland GmbH & Co. KG (DE) | 2014-05-29 | — | — | US | claimed |
| US-8642598-B2 | Heterocyclic compounds and their use as glycogen synthase kinase 3 inhibitors | ABBVIE INC. (US) | 2014-02-04 | — | — | US | claimed |
| EP-2091943-B1 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS GLYCOGEN SYNTHASE KINASE 3 INHIBITORS | ABBVIE DEUTSCHLAND (DE) | 2013-11-20 | — | — | EP | claimed |
| EP-2535336-A1 | Heterocyclic compounds and their use as glycogen synthase kinase 3 inhibitors | Abbott GmbH & Co. KG (DE) | 2012-12-19 | — | — | EP | claimed |
| US-20100324042-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS GLYCOGEN SYNTHASE KINASE 3 INHIBITORS | ABBOTT GMBH & CO. KG. (DE) | 2010-12-23 | — | — | US | claimed |
| US-9856234-B2 | Heterocyclic compounds and their use as glycogen synthase kinase 3 inhibitors | AbbVie Deutschland GmbH & Co. KG (DE) | 2018-01-02 | — | — | US | disclosed |
| US-20140148458-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS GLYCOGEN SYNTHASE KINASE 3 INHIBITORS | AbbVie Deutschland GmbH & Co. KG (DE) | 2014-05-29 | — | — | US | disclosed |
| US-8642598-B2 | Heterocyclic compounds and their use as glycogen synthase kinase 3 inhibitors | ABBVIE INC. (US) | 2014-02-04 | — | — | US | disclosed |
| EP-2091943-B1 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS GLYCOGEN SYNTHASE KINASE 3 INHIBITORS | ABBVIE DEUTSCHLAND (DE) | 2013-11-20 | — | — | EP | disclosed |
| EP-2535336-A1 | Heterocyclic compounds and their use as glycogen synthase kinase 3 inhibitors | Abbott GmbH & Co. KG (DE) | 2012-12-19 | — | — | EP | disclosed |
| US-20100324042-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS GLYCOGEN SYNTHASE KINASE 3 INHIBITORS | ABBOTT GMBH & CO. KG. (DE) | 2010-12-23 | — | — | US | disclosed |
| EP-2091943-A2 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS GLYCOGEN SYNTHASE KINASE 3 INHIBITORS | Abbott GmbH & Co. KG (DE) | 2009-08-26 | — | — | EP | disclosed |
| WO-2008046919-A2 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS GLYCOGEN SYNTHASE KINASE 3 INHIBITORS | ABBOTT GMBH & CO. KG (DE) | 2008-04-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140148458-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS GLYCOGEN SYNTHASE KINASE 3 INHIBITORS | GSK3B, GSK3A, GYS2 | HTT 3830/4885GAA 209/4885MAPT 1039/4885 |
| US-20100324042-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS GLYCOGEN SYNTHASE KINASE 3 INHIBITORS | GSK3B, GSK3A, GYS2 | HTT 3830/4885GAA 209/4885MAPT 1039/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.